The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid

Ryuji Yasumatsu, Masanobu Sato, Ryutaro Uchi, Takafumi Nakano, Kazuki Hashimoto, Ryunosuke Kogo, masahiko taura, Mioko Matsuo, Torahiko Nakashima, Takashi Nakagawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Primary squamous cell carcinoma (SCC) of the thyroid is a rare disease. It usually presents with locally advanced disease and has an overall poor prognosis. In this study, we investigated the characteristics and outcomes of patients with SCC of the thyroid, and reported our experience with chemotherapy with lenvatinib in the treatment of SCC of the thyroid. Methods: The management outcome of 10 patients who had SCC of the thyroid between January 2000 and 2015 at Kyushu University Hospital or associated facilities was reviewed. Results: There were 3 males and 7 females, ranging in age from 53 to 77 years. Extent of disease was staged as follows: stage IVA, 3 cases; stage IVB, 3 cases; stage IVC, 4 cases. Only tracheostomy was applied for 2 cases, surgical resection, such as total thyroidectomy and neck dissection, for the other 8 cases. Radiotherapy following surgical treatment was applied for 9 cases. Four patients started on oral lenvatinib due to recurrent or progressive SCC of the thyroid. The one year actuarial survival rate of patients was 22.7%. There was no 2-year survivor of all patients. Conclusions: Treatment should primarily be targeted at surgical resection with negative margins in patients with resectable disease. Lenvatinib may show promise to potentially extend survival.

Original languageEnglish
Pages (from-to)553-557
Number of pages5
JournalAuris Nasus Larynx
Volume45
Issue number3
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Squamous Cell Carcinoma
Thyroid Gland
Neck Dissection
Tracheostomy
Thyroidectomy
Rare Diseases
Survivors
Radiotherapy
Therapeutics
Survival Rate
Drug Therapy
Survival
lenvatinib

All Science Journal Classification (ASJC) codes

  • Surgery
  • Otorhinolaryngology

Cite this

The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid. / Yasumatsu, Ryuji; Sato, Masanobu; Uchi, Ryutaro; Nakano, Takafumi; Hashimoto, Kazuki; Kogo, Ryunosuke; taura, masahiko; Matsuo, Mioko; Nakashima, Torahiko; Nakagawa, Takashi.

In: Auris Nasus Larynx, Vol. 45, No. 3, 01.06.2018, p. 553-557.

Research output: Contribution to journalArticle

Yasumatsu, Ryuji ; Sato, Masanobu ; Uchi, Ryutaro ; Nakano, Takafumi ; Hashimoto, Kazuki ; Kogo, Ryunosuke ; taura, masahiko ; Matsuo, Mioko ; Nakashima, Torahiko ; Nakagawa, Takashi. / The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid. In: Auris Nasus Larynx. 2018 ; Vol. 45, No. 3. pp. 553-557.
@article{58eca16a716b45058ebbb17cbebcdc1e,
title = "The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid",
abstract = "Objectives: Primary squamous cell carcinoma (SCC) of the thyroid is a rare disease. It usually presents with locally advanced disease and has an overall poor prognosis. In this study, we investigated the characteristics and outcomes of patients with SCC of the thyroid, and reported our experience with chemotherapy with lenvatinib in the treatment of SCC of the thyroid. Methods: The management outcome of 10 patients who had SCC of the thyroid between January 2000 and 2015 at Kyushu University Hospital or associated facilities was reviewed. Results: There were 3 males and 7 females, ranging in age from 53 to 77 years. Extent of disease was staged as follows: stage IVA, 3 cases; stage IVB, 3 cases; stage IVC, 4 cases. Only tracheostomy was applied for 2 cases, surgical resection, such as total thyroidectomy and neck dissection, for the other 8 cases. Radiotherapy following surgical treatment was applied for 9 cases. Four patients started on oral lenvatinib due to recurrent or progressive SCC of the thyroid. The one year actuarial survival rate of patients was 22.7{\%}. There was no 2-year survivor of all patients. Conclusions: Treatment should primarily be targeted at surgical resection with negative margins in patients with resectable disease. Lenvatinib may show promise to potentially extend survival.",
author = "Ryuji Yasumatsu and Masanobu Sato and Ryutaro Uchi and Takafumi Nakano and Kazuki Hashimoto and Ryunosuke Kogo and masahiko taura and Mioko Matsuo and Torahiko Nakashima and Takashi Nakagawa",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.anl.2017.07.009",
language = "English",
volume = "45",
pages = "553--557",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - The treatment and outcome analysis of primary squamous cell carcinoma of the thyroid

AU - Yasumatsu, Ryuji

AU - Sato, Masanobu

AU - Uchi, Ryutaro

AU - Nakano, Takafumi

AU - Hashimoto, Kazuki

AU - Kogo, Ryunosuke

AU - taura, masahiko

AU - Matsuo, Mioko

AU - Nakashima, Torahiko

AU - Nakagawa, Takashi

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Objectives: Primary squamous cell carcinoma (SCC) of the thyroid is a rare disease. It usually presents with locally advanced disease and has an overall poor prognosis. In this study, we investigated the characteristics and outcomes of patients with SCC of the thyroid, and reported our experience with chemotherapy with lenvatinib in the treatment of SCC of the thyroid. Methods: The management outcome of 10 patients who had SCC of the thyroid between January 2000 and 2015 at Kyushu University Hospital or associated facilities was reviewed. Results: There were 3 males and 7 females, ranging in age from 53 to 77 years. Extent of disease was staged as follows: stage IVA, 3 cases; stage IVB, 3 cases; stage IVC, 4 cases. Only tracheostomy was applied for 2 cases, surgical resection, such as total thyroidectomy and neck dissection, for the other 8 cases. Radiotherapy following surgical treatment was applied for 9 cases. Four patients started on oral lenvatinib due to recurrent or progressive SCC of the thyroid. The one year actuarial survival rate of patients was 22.7%. There was no 2-year survivor of all patients. Conclusions: Treatment should primarily be targeted at surgical resection with negative margins in patients with resectable disease. Lenvatinib may show promise to potentially extend survival.

AB - Objectives: Primary squamous cell carcinoma (SCC) of the thyroid is a rare disease. It usually presents with locally advanced disease and has an overall poor prognosis. In this study, we investigated the characteristics and outcomes of patients with SCC of the thyroid, and reported our experience with chemotherapy with lenvatinib in the treatment of SCC of the thyroid. Methods: The management outcome of 10 patients who had SCC of the thyroid between January 2000 and 2015 at Kyushu University Hospital or associated facilities was reviewed. Results: There were 3 males and 7 females, ranging in age from 53 to 77 years. Extent of disease was staged as follows: stage IVA, 3 cases; stage IVB, 3 cases; stage IVC, 4 cases. Only tracheostomy was applied for 2 cases, surgical resection, such as total thyroidectomy and neck dissection, for the other 8 cases. Radiotherapy following surgical treatment was applied for 9 cases. Four patients started on oral lenvatinib due to recurrent or progressive SCC of the thyroid. The one year actuarial survival rate of patients was 22.7%. There was no 2-year survivor of all patients. Conclusions: Treatment should primarily be targeted at surgical resection with negative margins in patients with resectable disease. Lenvatinib may show promise to potentially extend survival.

UR - http://www.scopus.com/inward/record.url?scp=85025140634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025140634&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2017.07.009

DO - 10.1016/j.anl.2017.07.009

M3 - Article

C2 - 28739190

AN - SCOPUS:85025140634

VL - 45

SP - 553

EP - 557

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 3

ER -